NCT05449366View on ClinicalTrials.gov

Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

June 1, 2025

Study Completion Date

August 1, 2025

Conditions
Peritoneal Malignant Mesothelioma
Interventions
DRUG

Intraperitoneal Paclitaxel Solution (Ml)

Weekly cycles of intraperitoneal paclitaxel monotherapy

Trial Locations (1)

3000 CA

Erasmus Medical Center, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER